Zoetis: brands it owns and its ownership tree
Zoetis (NYSE: ZTS) is a publicly listed company headquartered in Parsippany, New Jersey, United States that owns 17 consumer brands.[1][2]
Zoetis is the largest animal health company in the world by revenue, selling medicines, vaccines and diagnostics for pets and livestock. It was incorporated in Delaware in July 2012 out of what had been a business unit of Pfizer, and it markets directly in about 45 countries while selling in more than 100. Companion animals now dominate: its two biggest lines, the Simparica parasiticides and the Apoquel dermatology range, were 16 and 12 per cent of 2025 revenue, and it left the medicated feed additive business entirely in 2024.
-
brands owned
-
1
categories
-
0
acquisitions recorded
-
0
divestitures recorded
Company facts
- Legal name
- Zoetis Inc.
- Type
- publicly listed company · see all publicly listed company owners
- Headquarters
- 🇺🇸 Parsippany, New Jersey, United States
- Founded
- 2012
- Tickers
- NYSE: ZTS
- Revenue
- $9.47 billion (2025)[2]
- SEC CIK
- 0001555280
- Website
- www.zoetis.com
- Last verified
- · 2 sources
What Zoetis's annual report says about its business
Read from Zoetis's latest annual filing[1]. Each line gives the sentence the filing uses, copied word for word.
Segments the filing names
- United States, International:
As a result of these differences, among other things, we organize and operate our business in two segments: United States (U.S.) with revenue of $5,097 million, or 54% of total revenue for the year ended December 31, 2025; and International with revenue of $4,254 million, or 45% of total revenue for the year ended December 31, 2025.
Acquisitions and disposals named in the filing
- Acquired: Abaxis, Inc. (2018).
Zoetis enhanced the portfolio of its diagnostic products with the acquisition in 2018 of Abaxis, Inc. (Abaxis), a leading provider of veterinary point-of-care diagnostic instruments, including the Vetscan portfolio of benchtop and handheld diagnostic instruments and consumables.
- Acquired: Jurox (2022).
In 2022, the company completed the acquisition of Jurox, an animal health company based in Australia, which brings the company a range of companion animal and livestock products and provides the company with future growth opportunities, manufacturing capacity and increased capabilities in Australia.
- Acquired: Basepaws (2022).
Also in 2022, the company acquired Basepaws, a petcare genetics company that provides pet owners with genetic tests, analytics and early health risk assessments, which help pet owners and veterinarians understand an individual pet's risk for disease and helps Zoetis identify solutions to complex diseases by informing our research and innovation.
- Acquired: PetMedix Ltd (2023).
In 2023, the company completed the acquisition of PetMedix Ltd, a privately held research and development stage animal health biopharmaceutical company based in the U.K., which develops antibody-based therapeutics for companion animals.
- Acquired: adivo GmbH (2023).
Also in 2023, the company completed the acquisition of adivo GmbH, a privately held research and development stage animal health biopharmaceutical company based in Germany.
- Acquired: Veterinary Pathology Group (2025).
In 2025, the company acquired Veterinary Pathology Group, a leading veterinary diagnostic laboratory group with multiple locations across the U.K. and Ireland.
- Acquired: a manufacturing site outside Atlanta, Georgia (2023).
Additionally, we purchased a manufacturing site outside Atlanta, Georgia in 2023, where we plan to begin commercial production in the future.
Zoetis in numbers
- Zoetis owns 17 consumer brands tracked here across 1 top-level categories; the largest is pet & animal care with 17 brands.[1]
Zoetis financial history
Headline figures from Zoetis's annual reports filed with the US Securities and Exchange Commission, in USD as reported, fiscal years ending 2020–2025. Revenue moved from $6.67bn to $9.47bn, an average of 7.2% a year (calculated).
| Fiscal year ended | Revenue | Operating income | Operating margin | Net income | Total assets | Long-term debt | Filing |
|---|---|---|---|---|---|---|---|
| $9.47bn | — | — | $2.67bn | $15.5bn | $9.04bn | 10-K | |
| $9.26bn | — | — | $2.49bn | $14.2bn | $5.22bn | 10-K | |
| $8.54bn | — | — | $2.34bn | $14.3bn | $6.56bn | 10-K | |
| $8.08bn | — | — | $2.11bn | $14.9bn | $6.55bn | 10-K | |
| $7.78bn | — | — | $2.04bn | $13.9bn | $6.59bn | 10-K | |
| $6.67bn | — | — | $1.64bn | $13.6bn | $6.59bn | 10-K |
Source: SEC XBRL company facts. A dash means the company did not report that line in a form we could read. Figures for a year can be restated in a later filing; the latest filing's number is shown.
Everything Zoetis owns
Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.
Full-screen interactive tree → · Download as infographic
Brand portfolio by category
Recent changes to this record
Zoetis SEC filings
The documents behind the figures on this page, as listed in the SEC's EDGAR index. Each links to the filing itself.
Annual reports
- Annual report, filed (10-K)
- Annual report, filed (10-K)
- Annual report, filed (10-K)
- Annual report, filed (10-K)
- Annual report, filed (10-K)
- Annual report, filed (10-K)
Proxy statements
- Proxy statement, filed (DEF 14A)
- Proxy statement, filed (DEF 14A)
- Proxy statement, filed (DEF 14A)
Recent current and quarterly reports
| Filed | Form | What it declares |
|---|---|---|
| 8-K | Regulation FD disclosure | |
| 8-K | Departure or appointment of directors or officers | |
| 10-Q | Quarterly report | |
| 8-K | Results of operations and financial condition | |
| 8-K | Departure or appointment of directors or officers; Results of a shareholder vote | |
| 8-K | Regulation FD disclosure | |
| 10-Q | Quarterly report | |
| 8-K | Results of operations and financial condition | |
| 8-K | Results of operations and financial condition | |
| 8-K | Regulation FD disclosure | |
| 8-K | Entry into a material agreement; Creation of a direct financial obligation; Unregistered sales of equity securities; Regulation FD disclosure | |
| 8-K | Regulation FD disclosure | |
| 8-K | Other events | |
| 10-Q | Quarterly report |
Frequently asked questions
What brands does Zoetis own?
Zoetis owns 17 consumer brands tracked here, including Vetscan, Vanguard, Apoquel, Solensia, Revolution and Poulvac.
Is Zoetis an American company?
Yes. Zoetis is headquartered in Parsippany, New Jersey, United States and was founded in 2012.
Who owns Zoetis?
Zoetis is a publicly listed company owned by its shareholders; it trades as ZTS on the NYSE.
Sources (2) & corrections
Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.
- [1] Zoetis Inc. Annual Report on Form 10-K filed 2026-02-12 — SEC EDGAR, SEC Form 10-K, published 12 February 2026; retrieved 25 September 2026.
- [2] Zoetis Inc.: Form 10-K for the year ended 2025-12-31 (revenue) — SEC EDGAR, SEC Form 10-K, published 12 February 2026; retrieved 4 October 2026.
Report a correction Opens a pre-filled GitHub issue. See our corrections policy.